

GezmiÅ Kimyon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8988664/publications.pdf>

Version: 2024-02-01

28
papers

343
citations

1040056

9
h-index

839539

18
g-index

28
all docs

28
docs citations

28
times ranked

658
citing authors

#	ARTICLE	IF	CITATIONS
1	Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. <i>Journal of Autoimmunity</i> , 2016, 69, 59-63.	6.5	62
2	Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2015, 42, 1661-1666.	2.0	43
3	Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study. <i>Journal of Rheumatology</i> , 2016, 43, 893-900.	2.0	36
4	The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. <i>Rheumatology</i> , 2017, 56, 279-286.	1.9	29
5	Isotretinoin-induced Spondyloarthropathy-related Symptoms: A Prospective Study. <i>Journal of Rheumatology</i> , 2015, 42, 2106-2109.	2.0	26
6	Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. <i>Clinical Rheumatology</i> , 2018, 37, 3443-3448.	2.2	24
7	Effect of Chronic Periodontitis on Oxidative Status in Patients With Psoriasis and Psoriatic Arthritis. <i>Journal of Periodontology</i> , 2016, 87, 557-565.	3.4	20
8	The evaluation in terms of sarcopenia of patients with fibromyalgia syndrome. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 816-821.	1.9	20
9	Three cases of anti-TNF induced myositis and literature review. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 590-595.	0.7	15
10	Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results. <i>American Journal of Ophthalmology</i> , 2021, 228, 58-64.	3.3	10
11	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 532-536.	0.8	8
12	Methodology of a new inflammatory arthritis registry: TReasure. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 856-861.	0.9	7
13	Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 77-82.	0.8	7
14	Current Smoking Is Increased in Axial Psoriatic Arthritis and Radiographic Sacroiliitis. <i>Journal of Rheumatology</i> , 2020, 47, 1354-1358.	2.0	6
15	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1615-1623.	0.9	6
16	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. <i>Clinical and Experimental Rheumatology</i> , 0, .	0.8	6
17	Internal jugular vein thrombosis in Behcet's disease: a rare complication. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013200261-bcr2013200261.	0.5	5
18	PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1755-1762.	1.9	4

#	ARTICLE	IF	CITATIONS
19	TNF-alpha, IL-6, IL-10 and fatty acids in rheumatoid arthritis patients receiving cDMARD and bDMARD therapy. <i>Clinical Rheumatology</i> , 2022, 41, 2341-2349.	2.2	4
20	Patientsâ€™ concerns regarding biological agents in rheumatology. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1219-1226.	1.9	2
21	Corneal biomechanical parameters in systemic autoimmune diseases. <i>Australasian journal of optometry</i> , The, 2021, , 1-4.	1.3	1
22	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. <i>Rheumatology International</i> , 2021, 41, 1915-1924.	3.0	1
23	Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 852-858.	0.8	1
24	Large joint and lower extremity involvement have higher impact on disease outcomes in oligoarticular psoriatic arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1094-1099.	1.9	0
25	Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry. <i>European Journal of Rheumatology</i> , 2020, 7, 64-67.	0.6	0
26	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 532-536.	0.8	0
27	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
28	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. <i>Rheumatology International</i> , 2022, 42, 1797-1806.	3.0	0